Ethan Stortz and Helen Lawler
JCEM Case Reports, Volume 2, Issue 11, November 2024, luae194
https://doi.org/10.1210/jcemcr/luae194
Early dumping syndrome (DS) and postbariatric hypoglycemia (PBH) are challenging conditions with limited treatment options. A 46-year-old woman with prediabetes, obesity, and sleeve gastrectomy presented with digestive symptoms suggestive of DS and postprandial hypoglycemia consistent with PBH. She started tirzepatide 2.5 mg weekly, which decreased postprandial blood glucose peaks, increased postprandial blood glucose nadirs, and improved overall time in range on continuous glucose monitoring (CGM). Her postprandial bloating and diarrhea resolved. To our knowledge, there have been no reported cases of DS or PBH treated with dual-incretin agonists. While glucagon-like peptide-1 (GLP-1) agonists have not been widely attempted in DS and have shown mixed benefit for PBH, combination GLP-1 and gastric inhibitory peptide agonism may represent a novel treatment both for PBH and DS, providing greater improvement in glycemic variation as well as better DS control than GLP-1 agonism alone.
We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.
